Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 19/20 | 0.69 |
| ▸ | THRA | P10827 | 18/20 | 0.69 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373597 | 1.00 | THRB (0.69) | THRBTHRASLC7A5 | |
| SCHEMBL23003762 | 0.91 | THRB (0.66) | THRBTHRA | |
| SCHEMBL20601960 | 0.87 | THRB (0.67) | THRBTHRA | |
| SCHEMBL23003728 | 0.86 | THRB (0.65) | THRBTHRASLC7A5 | |
| SCHEMBL19508336 | 0.85 | THRB (0.54) | THRBTHRASLC7A5 | |
| SCHEMBL12824840 | 0.85 | THRB (0.57) | THRBTHRASLC7A5 | |
| SCHEMBL23003721 | 0.84 | THRB (0.57) | THRBTHRA | |
| Vk-0214 SCHEMBL283442 | 0.84 | THRB (0.79) | THRBTHRASLC7A5 | |
| SCHEMBL25856594 | 0.83 | THRB (0.67) | THRBTHRASLC7A5 | |
| SCHEMBL22071776 | 0.82 | THRB (0.62) | THRBTHRASLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | claimed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | claimed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | claimed |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | disclosed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20100021416-A1 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100015263-A1 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-7302347-B2 | Method for creating specific, high affinity nuclear receptor pharmaceuticals | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-27 | — | — | US | disclosed |
| US-7302347-B2 | Method for creating specific, high affinity nuclear receptor pharmaceuticals | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-27 | — | — | US | disclosed |
| US-20040253648-A1 | Method for creating nuclear receptor activity modulating pharmaceuticals | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-12-16 | — | — | US | disclosed |
| WO-2004052303-A2 | A METHOD FOR CREATING NUCLEAR RECEPTOR ACTIVITY MODULATING PHARMACEUTICALS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052302-A2 | A METHOD FOR CREATING SPECIFIC, HIGH AFFINITY NUCLEAR RECEPTOR PHARMACEUTICALS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015263-A1 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, MYOC, S100B | THRB 1555/4885THRA 1522/4885SLC7A5 2150/4885 |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | THRB 2/4885THRA 1/4885SLC7A5 3427/4885 |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | THRB 3286/4885THRA 1945/4885SLC7A5 981/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | THRB 429/4885THRA 311/4885SLC7A5 1350/4885 |
| US-20100021416-A1 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, TLR3, STING1 | THRB 2404/4885THRA 1919/4885SLC7A5 1657/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | THRB 3286/4885THRA 1945/4885SLC7A5 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.